179th Day Of Lockdown

Maharashtra114584081235431351 Andhra Pradesh6095585198915244 Tamil Nadu5309084757178685 Karnataka5029823940257808 Uttar Pradesh3362942632884771 Delhi2347011981034877 West Bengal2155801870614183 Odisha167161133466722 Telangana1670461353571016 Bihar164224149722855 Assam150349121610528 Kerala12221687341490 Gujarat119088999083271 Rajasthan109088906851293 Haryana103773816901069 Madhya Pradesh97906743981877 Punjab90032658182646 Chhatisgarh7777541111628 Jharkhand6710052807590 Jammu and Kashmir5971138521951 Uttarakhand3713924810460 Goa2678320844327 Puducherry2142816253431 Tripura2069612956222 Himachal Pradesh11190691997 Chandigarh92566062106 Manipur8430653951 Arunachal Pradesh6851496713 Nagaland5306407910 Meghalaya4356234232 Sikkim2119178923 Mizoram15069490
Business Companies 13 Aug 2020 J&J ties up with ...

J&J ties up with Biological E for manufacturing Covid vaccine in India

DECCAN CHRONICLE.
Published Aug 13, 2020, 8:57 pm IST
Updated Aug 13, 2020, 9:18 pm IST
Hyderabad firm ties up to produce J&J's vaccine candidate in India
Mahima Datla, the managing director of Biological E
 Mahima Datla, the managing director of Biological E

Hyderabad: Biological E. Limited, India’s oldest biological products company, said on Thursday that it has tied up US-based Johnson & Johnson to manufacture the latter’s Covid-19 vaccine candidate in India.

“We are very pleased indeed to collaborate with an organisation like Johnson & Johnson. Given the magnitude of the Covid-19 pandemic, our ability to mount an effective response will be predicated on the ability to supply the vaccine globally and in significant quantities. This is best achieved through collaboration,” said Mahima Datla, the managing director of BE.

 

J&J is developing a vaccine candidate ‘Ad26.COV2.S’ for Coronavirus through its pharmaceutical arm Janssen Pharmaceutica NV. The vaccine candidate is currently in Phase 1/2a clinical trials.

The phase 1/2a study will involve more than 1,000 adults aged between 18 and 55. The study will also include an arm testing the vaccine in people 65 and older. Human trials in the Netherlands, Spain, Germany and Japan will follow.

Johnson & Johnson chief scientific officer Paul Stoffels had told a conference call last month that the company expects initial human results in September and phase 3 efficacy testing could start the same month itself. “The vaccine could be ready by early 2021,” he said.

 

The tie-up with Biological E. would help J&J to ramp its manufacturing capabilities in India.

“We look forward to deploying our manufacturing infrastructure to support Johnson & Johnson’s commitment to global access for its COVID-19 vaccine,” said Narender Dev Mantena, Director of BioE Holdings Inc., who heads BE’s novel vaccine initiative.

According to the World Health Organisation data, people around the world are working on 42 vaccine candidates for Coronavirus, including two from India, which are at different stages of development.

 

“Six vaccine candidates are in phase-3 trials, two candidates in phase 2 trials. Ten vaccine candidates, including two being developed in India, are at phase ½,” claims the WHO data as on August 10.

...




ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT